ID   K562 DAS
AC   CVCL_E6HX
SY   K562 200nM DAS
RX   PubMed=21718141;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_49375; Dasatinib (BMS-354825).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:76; ABL1; Simple; p.Thr315Ile (c.944C>T) (c.1001C>T); ClinVar=VCV000012624; Zygosity=Unspecified; Note=Acquired during resistance selection process (PubMed=21718141).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=21718141; DOI=10.3109/10428194.2011.591013;
RA   Tang C., Schafranek L., Watkins D.B., Parker W.T., Moore S., Prime J.A.,
RA   White D.L., Hughes T.P.;
RT   "Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell
RT   lines: investigating resistance pathways.";
RL   Leuk. Lymphoma 52:2139-2147(2011).
//